What Is RMD Fair Value?
ResMed (RMD) fair value estimate using multiple valuation models, updated daily.
As of July 16, 2026, ResMed (RMD) has a composite fair value estimate of $203.50 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $198.57, suggesting the stock is fair value by 2.5%.
Data as of July 16, 2026 (today)
Composite Fair Value
Fair Value4 of 4 models$203.50
vs. current price of $198.57(+2.5%)
How Is RMD Fair Value Calculated?
Four independent models estimate what RMD is worth. Each uses different inputs and assumptions. The composite blends them by weight.
RMD Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$309.02
+55.6%Undervalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$101.08
-49.1%Overvalued
Inputs used
RMD Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$105.76
-46.7%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$138.62
-30.2%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $198.57 is 55.6% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $1.63B | $1.50B |
| Year 2 | $1.83B | $1.55B |
| Year 3 | $2.06B | $1.61B |
| Year 4 | $2.32B | $1.66B |
| Year 5 | $2.60B | $1.72B |
| Year 6 | $2.93B | $1.78B |
| Year 7 | $3.30B | $1.85B |
| Year 8 | $3.71B | $1.91B |
| Year 9 | $4.17B | $1.98B |
| Year 10 | $4.69B | $2.05B |
| Terminal Value | $78.47B | $34.31B |
What Are RMD's Key Financial Metrics?
Earnings & Growth
Current Price
$198.57
EPS (TTM)
$10.66
Forward P/E
16.5
Profit Margin
27.4%
Cash & Balance Sheet
Free Cash Flow
1.4B
EBITDA
2.1B
Book Value
$44.76
Total Debt
843.2M
What Do Analysts Say About RMD?
Low
$180.00
Average
$252.20
High
$325.00
Upside
+27.0%
RMD Fair Value FAQ
What is the fair value of RMD?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), RMD's estimated fair value is $203.50. The stock is currently trading at $198.57, which makes it fair value by our analysis.
How is RMD's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is RMD overvalued or undervalued?
Based on our analysis, RMD is fair value. The current price of $198.57 is 2.5% below our estimated fair value of $203.50.
What do Wall Street analysts say about RMD?
15 analysts cover ResMed with a consensus rating of "Buy." The average price target is $252.20, ranging from $180.00 to $325.00. This implies 27.0% upside from the current price.